Pharma Mar
€70.75Change from previous close: −3.21%Absolute change: −€2.35
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €1.22B
- Enterprise value
- €1.14B
- P/E (trailing 12 months)
- 22.0
- Forward P/E
- 10.8
- PEG
- 0.31
- Price/book
- 4.89
- Price/sales
- 5.59
- EV/EBITDA
- 25.5
- EV/revenue
- 5.23
Profitability and growth
- Gross margin
- 93.4%
- Operating margin
- -2.8%
- Net margin
- 25.7%
- ROE
- 24.8%
- ROA
- 6.5%
- Revenue growth (year over year)
- -12.0%
Financial health
- Total cash
- €168.88M
- Total debt
- €45.84M
- Debt/equity
- 0.18
- Current ratio
- 2.86
- Quick ratio
- 2.20
Dividends
- Annual dividend per share
- €1.00
- Dividend yield
- 1.4%
- Payout ratio
- 0.0%
- Ex-dividend date
- July 8, 2026
Analysts and estimates
- Average price target
- €102.94
- Median price target
- €98.00
- High price target
- €125.00
- Low price target
- €85.50
- Analysts with a price target
- 8
- Consensus
- Buy
- Forward EPS
- €6.56
- EPS estimate, current year
- €1.87
Shares and trading
- Beta
- 0.43
- Average volume
- 40.02K
- Shares outstanding
- 17.29M
- Float
- 13.4M
- Institutional ownership
- 10.3%
- Insider ownership
- 27.2%